Biotech · Private company
TCR2 Therapeutics
Track this companyFree. Adds TCR2 Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials31 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline9
- cyclophosphamidePhase 2 · MesotheliomaClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 2 · Non Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- fludarabinePhase 2 · MesotheliomaClinicalTrials.gov · fetched Nov 12, 2026
- FludarabinePhase 2 · Non Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- gavo-celPhase 2 · MesotheliomaClinicalTrials.gov · fetched Nov 12, 2026
- IpilimumabPhase 2 · MesotheliomaClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 2 · MesotheliomaClinicalTrials.gov · fetched Nov 12, 2026
- TC-110 T CellsPhase 2 · Non Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- TC-510Phase 2 · MesotheliomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing CancerPHASE1_PHASE2 · TERMINATED · started Jun 21, 2022ClinicalTrials.gov NCT05451849 · fetched Nov 12, 2026
- TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic LeukemiaPHASE1_PHASE2 · COMPLETED · started Mar 27, 2020ClinicalTrials.gov NCT04323657 · fetched Nov 12, 2026
- Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing CancerPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Apr 15, 2019ClinicalTrials.gov NCT03907852 · fetched Nov 12, 2026